Mobile

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in P...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003695-35

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-cancer Therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to demonstrate an improvement in PFS as assessed by RECIST criteria, for the combination of ZD6474 plus pemetrexed (Alimta®) compared with pemetrexed plus placebo in patients with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy (not including an adjuvant regimen).

Critère d'inclusion

  • Locally-advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC)

Liens